3 research outputs found
Lymphocytic hypophysitis and hypothalamitis - a case report
Limfocytarne zapalenie przysadki jest rzadkim procesem
chorobowym dotyczącym przede wszystkim kobiet. W niniejszej
pracy przedstawiono przypadek 69-letniej pacjentki,
u której wystąpiły objawy moczówki prostej oraz niewydolność
części gruczołowej przysadki w zakresie czynności
gonado- i kortykotropowej z wtórną niewydolnością
kory nadnerczy. W obrazie rezonansu magnetycznego uwidoczniono
naciek w okolicy podwzgórzowo-przysadkowej.
W związku z wykluczeniem innych przyczyn nacieku tej
okolicy oraz dobrą reakcją na dożylną steroidoterapię rozpoznano
limfocytarne zapalenie okolicy przysadkowo-podwzgórzowej.Lymphocytic hypophysitis is an unusual disorder that nearly
exclusively affects women.
We present a case of 69 year-old female patient who developed
the symptoms of diabetes insipidus and partial insufficiency
of the anterior pituitary gland. Magnetic resonance
imaging of the brain revealed a mass involving the
sella and suprasellar region.
After exclusion of other causes of infiltrate in this region
and due to evident reaction to glucocorticoid treatment the
diagnosis of lymphocytic hypophisitis and hypothalamitis
was established
The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours
Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from
Aim of the study: To assess resource utilization
and costs of treatment with lanreotide
AUTOGEL 120 mg (ATG120)
administered as part of routine acromegaly care in Poland.
Material and methods: A multicentre,
non-interventional, observational study
on resource utilization in Polish acromegalic
patients treated with ATG120 at
4 weeks or extended (> 4 weeks) dosing
interval. The study recruited adult acromegalic patients treated medically for
≥ 1 year including at least 3 injections of
ATG120. Data on dosing interval, aspects
of administration, and resource utilization
were collected prospectively during
12 months. Costs were calculated in PLN
from the public health-care payer perspective
for the year 2013.
Results: 139 patients were included in
the analysis. Changes in dosing regimen
were reported in 14 (9.4%) patients. Combined
treatment was used in 11 (8%) patients. Seventy patients (50%) received
ATG120 at an extended dosing interval;
the mean number of days between
injections was 35.56 (SD 8.4). ATG120
was predominantly administered in an
out-patient setting (77%), by health-care
professionals (94%). Mean time needed
for preparation and administration was
4.33 and 1.58 min, respectively, mean
product wastage - 0.13 mg. Patients were
predominantly treated in an out-patient
setting with 7.06 physician visits/patient/
year. The most common control examinations
were magnetic resonance imaging
of brain and brain stem (1.36/
patient/year), ultrasound of the neck
(1.35/patient/year), GH (1.69/pa tient/
year), glycaemia (1.12/patient/year),
IGF-1 (0.84/patient/year), pituitary-thyroid
axis hormone levels assessment
(TSH-0.58/patient/year, T4-0.78/patient/
year). There were 0.43 hospitalizations/
patient/year. For direct medical
costs estimated at PLN 50 692/pa tient/
year the main item was the costs of
ATG120 (PLN 4103.87/patient/month;
97%). The mean medical cost, excluding
pharmacotherapy, was PLN 1445/patient/year (out-patient care - 49%, hospitalization
- 23%, diagnostics/laboratory
tests - 28%).
Conclusions: These results represent
the current use of ATG120 in the population
of Polish acromegalic patients in
a realistic clinical setting. Findings that
50% of patients could be treated with
dose intervals of longer than 28 days
support the potential of ATG120 to
reduce the treatment burden